Microscopic polyangiitis associated with pulmonary fibrosis

Marcelo Fernandez Casares1, Alejandra Gonzalez, Mariano Fielli

  • 1Department of Medicine, Pulmonary Section, Hospital Nacional A. Posadas, Illia s/n y Marconi, El Palomar, Buenos Aires, Argentina, mfercasar@intramed.net.ar.

Insights

Microscopic polyangiitis (MPA) with pulmonary fibrosis (PF) affects 32% of patients and presents with more respiratory symptoms and higher mortality. Pulmonary fibrosis often appears before other MPA symptoms, indicating a poor prognosis.

Area of Science:

  • Rheumatology
  • Pulmonology
  • Pathology

Background:

  • Microscopic polyangiitis (MPA) is a small vessel vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCAs).
  • Diffuse alveolar hemorrhage (DAH) is a known pulmonary manifestation, but pulmonary fibrosis (PF) is an increasingly recognized association.
  • Pulmonary fibrosis may precede or coincide with other MPA manifestations.

Purpose of the Study:

  • To evaluate MPA patients with pulmonary fibrosis (MPA-PF).
  • To compare the characteristics and outcomes of MPA-PF patients with those without PF (MPA-non PF).

Main Methods:

  • Retrospective review of MPA patients over 15 years.
  • Classification into MPA-PF and MPA-non PF subgroups.
  • Comparison of clinical and functional features between subgroups.

Main Results:

  • 32% of MPA patients had pulmonary fibrosis (MPA-PF).
  • The MPA-PF subgroup exhibited significantly more respiratory symptoms and higher mortality.
  • Usual interstitial pneumonia was the most common CT pattern in MPA-PF.
  • Pulmonary fibrosis preceded or occurred simultaneously with other vasculitis manifestations in all MPA-PF cases.
  • Four deaths occurred in the MPA-PF subgroup versus none in the MPA-non PF subgroup.

Conclusions:

  • Pulmonary fibrosis is a significant finding in a substantial proportion of MPA patients.
  • MPA patients with PF face a poorer prognosis, characterized by increased respiratory symptoms and mortality.
  • Pulmonary fibrosis can be an early or initial indicator of microscopic polyangiitis.

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
658
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
28
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
82
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
32
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
30
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
904